Comparison of the Efficacy of Piperacillin/Tazobactam and Meropenem, with or without Intravenous Immunoglobulin, as Second-Line Therapy for Febrile Neutropenia: A Prospective, Randomized Study

Abstract Warm antibody hemolytic anemia is the most common form of autoimmune hemolytic anemia. When therapy is needed, corticosteroids remain the cornerstone of initial treatment but are able to cure only a minority of patients (<20%). Splenectomy is usually proposed when a second-line therapy is needed. This classical approach is now challenged by the use of rituximab both as second-line and as first-line therapy. Second-line treatment with rituximab leads to response rates similar to splenectomy (∼70%), but rituximab-induced responses seem less sustained. However, additional courses of rituximab are most often followed by responses, at the price of reasonable toxicity. In some major European centers, rituximab is now the preferred second-line therapy of warm antibody hemolytic anemia in adults, although no prospective study convincingly supports this attitude. A recent randomized study strongly suggests that in first-line treatment, rituximab combined with steroids is superior to monotherapy with steroids. If this finding is confirmed, rituximab will emerge as a major component of the management of warm antibody hemolytic anemia not only after relapse but as soon as treatment is needed.

Download Full-text

Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy

Anticancer Research ◽

10.21873/anticanres.14923 ◽

2021 ◽

Vol 41 (3) ◽

pp. 1615-1620

Author(s):

YUKINA SATO ◽

HIROTOSHI IIHARA ◽

MOTOHIKO KINOMURA ◽

CHIEMI HIROSE ◽

HIRONORI FUJII ◽

...

Keyword(s):

Lung Cancer ◽

Febrile Neutropenia ◽

Cancer Patients ◽

Primary Prophylaxis ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Lung Cancer Patients ◽

Line Therapy

Download Full-text

PD-070 SIGN: A Phase II, open-label, randomized study comparinggefitinib (IRESSA) with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Lung Cancer ◽

10.1016/s0169-5002(05)80403-9 ◽

2005 ◽

Vol 49 ◽

pp. S87 ◽

Cited By ~ 1

Author(s):

T. Cufer ◽

E. Vrdoljak

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Advanced Stage ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

Targeted Oncology ◽

10.1007/s11523-007-0042-9 ◽

2007 ◽

Vol 2 (2) ◽

pp. 63-71

Author(s):

G. Robinet ◽

F. Barlesi ◽

P. Fournel ◽

H. Berard ◽

R. Corre ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Randomized Study ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Second Line Therapy ◽

Line Therapy

Download Full-text

Splenectomy Outcomes in Relapsed or Refractory Immune Thrombocytopenia According to First-Line Intravenous Immunoglobulin Response

Acta Haematologica ◽

10.1159/000521912 ◽

2022 ◽

Author(s):

Daehun Kwag ◽

Jae-Ho Yoon ◽

Gi June Min ◽

Sung-Soo Park ◽

Silvia Park ◽

...

Keyword(s):

Treatment Outcomes ◽

Intravenous Immunoglobulin ◽

Immune Thrombocytopenia ◽

Poor Responders ◽

Second Line ◽

First Line ◽

Second Line Therapy ◽

Line Therapy ◽

Refractory Itp ◽

Immunoglobulin Response

Introduction: Although splenectomy has long been second-line option for immune thrombocytopenia (ITP) patients, an indicator that reliably predicts the efficacy of splenectomy is still being explored. We investigated the treatment outcomes of splenectomy as a second-line therapy for relapsed/refractory ITP according to first-line intravenous immunoglobulin (IVIG) responses. Methods: Fifty-two adult patients treated with splenectomy as second-line therapy for ITP between 2009 and 2019 were included, and they were classified according to first-line IVIG responses (no response to IVIG: non-responders; only transient IVIG response shorter than 4 weeks: poor responders; IVIG response for a longer period; stable responders). The efficacy of splenectomy was analyzed in the three subgroups. Results: Of the 52 patients, 10 were IVIG non-responders, 34 were poor responders, and the remaining eight were stable responders. Response to splenectomy was observed in 50.0% of IVIG non-responders, 94.1% of poor responders, and 100% of stable responders (p = 0.0030). Among the 45 patients who responded to splenectomy, 51.1% relapsed subsequently, and a significantly lower relapse rate was noted in the stable IVIG responders (12.5%, p = 0.0220) than in non-responders (60.0%) and poor responders (59.4%). Conclusions: First-line IVIG response is indicated as a useful predictive factor for response to splenectomy.

Download Full-text

A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1).

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.cra8007 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. CRA8007-CRA8007 ◽

Cited By ~ 3

Author(s):

Suresh S. Ramalingam ◽

Glenwood D. Goss ◽

Zoran Gojko Andric ◽

Igor Bondarenko ◽

Bojan Zaric ◽

...

Keyword(s):

Heat Shock ◽

Heat Shock Protein ◽

Randomized Study ◽

Heat Shock Protein 90 ◽

Second Line ◽

Second Line Therapy ◽

Daily News ◽

Online Supplement ◽

Line Therapy ◽

Final Text

CRA8007 The full, final text of this abstract will be available at abstract.asco.org at 7:30 AM (EDT) on Monday, June, 3, 2013, and in the Annual Meeting Proceedings online supplement to the June 20, 2013, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Download Full-text